Metformin is used to treat type 2 diabetes by helping your body control blood sugar levels. It works by decreasing the amount of sugar your liver produces and helping your body use insulin more effectively.[2] Glucophage is currently approved and in use across 32 indications[4].[1]
Glucophage is one of 722 small molecule programs targeting Precocious Puberty. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
744 competitors in Breast Cancer
Glucophage
Voltaren
MS Contin
MS Contin
Tricor
Rilvegostomig
Vfend
Vit D
Ablavar
Liposomal Irinotecan and Apatinib
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Obese Patients
NCT06707012
Erythroplakia
NCT05237960
Study completion
NCT07785934
Pancreatic Cancer
NCT02336087
Breast Cancer
NCT05023967
Erythroplakia
NCT02581137
Clinical
Regulatory
Nov 5, 1998
GLUCOPHAGE
NDA NDA020357
Oct 13, 2000
GLUCOPHAGE XR
NDA NDA021202
Sep 11, 2003
RIOMET
NDA NDA021591
Apr 27, 2004
FORTAMET
NDA NDA021574
Jun 3, 2005
GLUMETZA
NDA NDA021748
Aug 29, 2019
RIOMET ER
NDA NDA212595
Sources
Details